CoGenesis® Ciliopathies

Ciliopathies are a group of inherited disorders caused by defects in cilia, the tiny hair-like structures present on many cells throughout the body. Cilia are essential for normal development, cell signaling, fluid movement, and organ function. When ciliary genes are altered, patients may develop multi-system disease affecting the kidneys, liver, eyes, brain, skeleton, heart, and respiratory tract. Because symptoms can overlap with other genetic conditions and vary greatly between families, ciliopathies are often difficult to diagnose using clinical features alone.

CoGenesis® Ciliopathies is a comprehensive NGS panel designed to evaluate a broad spectrum of genes linked to cilia-related disease biology. The panel includes core ciliopathy genes associated with Bardet-Biedl syndrome (for example BBS1, BBS2, BBS10, BBS12), nephronophthisis and renal ciliopathy pathways (for example NPHP1, NPHP3, INVS, PKD1, PKD2, PKHD1), Joubert and Meckel syndrome spectrum genes (for example AHI1, CC2D2A, CEP290, TMEM67, TCTN genes), and primary ciliary dyskinesia-associated genes (for example DNAH5, DNAH11, DNAI1, DNAAF genes, RSPH genes).

By testing many relevant genes in parallel, this panel supports earlier molecular diagnosis compared with sequential single-gene testing. A confirmed genetic finding can help clarify disease etiology, guide focused baseline evaluations (such as renal, ophthalmologic, neurologic, or hepatobiliary assessment), and inform recurrence-risk counseling for family planning. Results may also support referral to subspecialty care and consideration of condition-specific surveillance pathways where available.

As with other broad hereditary panels, a negative result does not fully exclude a ciliopathy diagnosis, and variants of uncertain significance (VUS) may be detected. Test findings should therefore be interpreted together with phenotype, imaging, and family history by clinicians experienced in medical genetics.

• Patients with clinical features suggestive of a ciliopathy spectrum disorder, including retinal dystrophy, cystic kidney disease, developmental delay, congenital anomalies, or recurrent sinopulmonary symptoms suggestive of primary ciliary dyskinesia.
• Individuals with suspected Bardet-Biedl syndrome, Joubert syndrome spectrum, nephronophthisis-related disease, Meckel syndrome spectrum, or other genetically heterogeneous cilia-related disorders.
• Cases where prior targeted single-gene testing was negative but inherited ciliary disease remains strongly suspected.
• Families requiring molecular confirmation to support genetic counseling, carrier testing in relatives, and recurrence-risk assessment for future pregnancies.
• Clinicians needing a broad first-line panel when phenotype overlaps multiple ciliopathy subtypes and differential diagnosis is wide.

6 sub-panels included:

4mL Peripheral blood (EDTA), 2mL saliva, or buccal swab

Preferred sample type:

• 4mL Blood (EDTA tube),
• Codex-provided buccal swabs (4 swabs)
• Codex-provided saliva collection kit (2mL)

Saliva or buccal swab sample collection: Follow the enclosed instructions; do not eat, drink, or smoke for 30 minutes before collection.

• Results may identify pathogenic, likely pathogenic, or variants of uncertain significance (VUS).
• Positive findings can inform risk‑reducing strategies and treatment options.
• Genetic counseling is recommended to help families understand implications.

Ciliopathies comprise a genetically and clinically diverse group of disorders resulting from dysfunction of motile or primary (non-motile) cilia. These organelles play central roles in developmental signaling pathways and tissue homeostasis; disruption can produce multi-organ phenotypes from infancy through adulthood. Inheritance is most commonly autosomal recessive, though X-linked and less common dominant presentations are recognized in selected genes.

Major clinical categories include syndromic ciliopathies (for example Bardet-Biedl syndrome, Joubert syndrome spectrum, Meckel syndrome spectrum, Alstrom syndrome), renal-hepatic ciliopathies (including nephronophthisis and polycystic kidney/liver disease pathways), retinal ciliopathies, and motile cilia disorders such as primary ciliary dyskinesia (PCD). Phenotypic overlap is substantial: the same gene may present with variable expressivity, and similar phenotypes may arise from different genes. This heterogeneity makes molecular testing particularly important for etiologic clarification.

The CoGenesis® Ciliopathies panel includes genes across key ciliary modules, such as BBSome/chaperonin genes (BBS1/BBS2/BBS10/BBS12/MKKS), transition-zone and basal-body genes (CEP290, TMEM67, CC2D2A, RPGRIP1L), intraflagellar transport genes (IFT122/IFT140/IFT172), nephrocystin-related pathways (NPHP genes), PKD/PKHD axis genes, and motile cilia axonemal assembly genes (DNAH, DNAI, DNAAF, RSPH families). Broad parallel testing increases diagnostic efficiency in patients whose presentation spans renal, ophthalmic, neurologic, respiratory, and developmental domains.

A molecular diagnosis can influence clinical management by enabling targeted organ surveillance, clarifying prognosis in context, and improving counseling for affected families. Interpretation should follow recognized variant-classification frameworks (for example ACMG/AMP principles) and be integrated with detailed phenotyping and family segregation data whenever possible.